Login to Your Account



GlycoVaxyn Finalizes Deal to Fund Bioconjugation Program

By Nuala Moran
Staff Writer

Wednesday, January 2, 2013
After landing the all-important validation of a deal with GlaxoSmithKline Biologicals in December, GlycoVaxyn AG is expecting to finalize an agreement to fund development of its lead in-house program and seal further collaborations around its conjugated vaccine technology platform in 2013.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription